Renaissance Technologies LLC Has $850,000 Stake in Core Laboratories Inc. $CLB

Renaissance Technologies LLC reduced its stake in Core Laboratories Inc. (NYSE:CLB) by 72.4% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 50,603 shares of the oil and gas company’s stock after selling 132,797 shares during the quarter. Renaissance Technologies LLC’s holdings in Core Laboratories were worth $850,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its stake in Core Laboratories by 185.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 845,251 shares of the oil and gas company’s stock worth $13,549,000 after acquiring an additional 548,657 shares during the period. Disciplined Growth Investors Inc. MN increased its position in shares of Core Laboratories by 9.7% in the third quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock worth $73,787,000 after purchasing an additional 528,976 shares during the period. MAC Alpha Capital Management LP acquired a new position in Core Laboratories in the fourth quarter valued at about $5,016,000. Heartland Advisors Inc. acquired a new position in Core Laboratories in the first quarter valued at about $2,518,000. Finally, T. Rowe Price Investment Management Inc. raised its stake in Core Laboratories by 14.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,042,208 shares of the oil and gas company’s stock valued at $16,707,000 after purchasing an additional 134,050 shares in the last quarter. Institutional investors and hedge funds own 97.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Johnson Rice upgraded shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Thursday. Finally, Weiss Ratings raised shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.00.

Insider Activity at Core Laboratories

In related news, CEO Lawrence Bruno bought 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was purchased at an average price of $10.78 per share, with a total value of $53,900.00. Following the completion of the acquisition, the chief executive officer owned 262,438 shares of the company’s stock, valued at $2,829,081.64. The trade was a 1.94% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.26% of the company’s stock.

Core Laboratories Trading Up 0.7%

Shares of CLB stock opened at $12.48 on Friday. Core Laboratories Inc. has a fifty-two week low of $9.79 and a fifty-two week high of $20.36. The stock’s fifty day moving average price is $11.60 and its two-hundred day moving average price is $14.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.55 and a current ratio of 2.12. The company has a market cap of $572.54 million, a PE ratio of 22.28, a P/E/G ratio of 3.00 and a beta of 1.03.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $124.61 million during the quarter, compared to the consensus estimate of $126.26 million. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.Core Laboratories’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 EPS. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Equities analysts predict that Core Laboratories Inc. will post 0.53 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Monday, August 10th will be paid a dividend of $0.01 per share. The ex-dividend date of this dividend is Monday, August 10th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories’s payout ratio is presently 7.14%.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.